A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

BMC Neurology

Table 4 Change from baseline in electrocardiogram categorical measures

Category	Post Baseline	Galcanezumab 120 mg		Galcanezumab 240 mg
Category	Post Baseline	N	n (%)	N	n (%)
Heart rate	< 50 bpm and decrease ≥15	117	1 (0.85)	131	1 (0.76)
Heart rate	> 100 bpm and increase ≥15	119	1 (0.84)	131	0
PR interval	< 120 msec	117	3 (2.56)	127	1 (0.79)
PR interval	≥ 220 msec	119	0	130	0
QRS interval	< 60 msec	120	0	131	0
QRS interval	≥120 msec	118	0	131	1 (0.76)
QTcF	< 330 msec for males, < 340 msec for females	118	0	130	0
	> 450 msec for males; > 470 msec for females	118	2 (1.69)	130	1 (0.77)
	Potentially clinically significant:
	> 500 msec	118	0	130	0
	Increase > 30 msec	118	2 (1.69)	130	4 (3.08)
	Increase > 60 msec	118	0	130	0

bpm beats per minute, PR pulse rate, QTcF QT interval adjusted for heart rate using Fridericia’s correction

ISSN: 1471-2377